Albino Penis Envy mushroom strain (APE)
- Species
- Psilocybe cubensis
- Also called
- APE, Albino PE
- Family
- Penis Envy family, Albino & leucistic
- Potency reputation
- very high
- Grow difficulty
- hard
- Yield
- low
Origin
John Workman of Sporeworks says he began developing APE around 2006 by crossing Penis Envy with PF Albino, then selecting and stabilizing the desired traits over several generations. Sources disagree on the timeline and parent: the psilocybea codex says it was first documented in the late 1990s, while the podcast description suggests the cross may have involved Albino A+; Workman’s account identifies PF Albino.
Lineage
Penis Envy crossed with PF Albino, according to creator John Workman; described by the psilocybea codex as a leucistic isolate of the Penis Envy lineage. Sources differ in whether they call it albino or leucistic.
Appearance
Typically has thick, robust, club-shaped stems and bulbous caps; fruiting bodies are ghost-white, sometimes with blue or gray-blue caps that may bruise deep blue. Sources describe APE as generally smaller than Penis Envy and producing few, clear spores.
Cultivation
Sources describe it as challenging to grow, slower to mature than typical cubensis varieties, prone to aborts, and a poor spore producer. The psilocybea codex labels its difficulty advanced.
Reported effects
Users are reported to describe APE as unusually intense or stronger than expected. A source notes that there is not enough evidence to establish a distinct subjective experience for particular cubensis varieties.
Good to know
Workman says he developed APE for its appearance, not to increase potency, and says he has never eaten a mushroom he grew.
Lab results
- Reported average psilocybin content for APE samples: about 0.93%.
- A sample attributed to cultivator Dr Greythumb was reported at 1.73% psilocybin and 0.61% psilocin combined.
Related
- Albino Penis Envy products and licensed brands
- Psilocybin, explained
- Licensed psilocybin centers in Oregon and Colorado
Sources
Psilocybin is a federally controlled substance. Legal adult access is limited to licensed programs in Oregon and Colorado. This profile is educational, not medical advice.